![Health / Medicine / Integrase inhibitors / GlaxoSmithKline / ViiV Healthcare / Lamivudine / Pfizer / Integrase / Raltegravir / Organofluorides / Chemistry / HIV/AIDS Health / Medicine / Integrase inhibitors / GlaxoSmithKline / ViiV Healthcare / Lamivudine / Pfizer / Integrase / Raltegravir / Organofluorides / Chemistry / HIV/AIDS](https://www.pdfsearch.io/img/51152d62f200fd67b0efcd447d1ac610.jpg) Date: 2014-11-03 11:26:21Health Medicine Integrase inhibitors GlaxoSmithKline ViiV Healthcare Lamivudine Pfizer Integrase Raltegravir Organofluorides Chemistry HIV/AIDS | | Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572)Add to Reading ListSource URL: shionogi616.tew-staging.comDownload Document from Source Website File Size: 25,12 KBShare Document on Facebook
|